392 related articles for article (PubMed ID: 33387580)
21. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
22. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
[TBL] [Abstract][Full Text] [Related]
23. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
24. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification.
Rouleau-Turcotte É; Pascal JM
J Biol Chem; 2023 Dec; 299(12):105397. PubMed ID: 37898399
[TBL] [Abstract][Full Text] [Related]
25. PARP-1 involvement in neurodegeneration: A focus on Alzheimer's and Parkinson's diseases.
Martire S; Mosca L; d'Erme M
Mech Ageing Dev; 2015 Mar; 146-148():53-64. PubMed ID: 25881554
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
Kam CM; Tauber AL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
[TBL] [Abstract][Full Text] [Related]
27. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose)polymerase-1 hyperactivation in neurodegenerative diseases: The death knell tolls for neurons.
Narne P; Pandey V; Simhadri PK; Phanithi PB
Semin Cell Dev Biol; 2017 Mar; 63():154-166. PubMed ID: 27867042
[TBL] [Abstract][Full Text] [Related]
29. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Badawy AA
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
[TBL] [Abstract][Full Text] [Related]
31. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
Zheng M; Mex M; Götz KH; Marx A
Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
[TBL] [Abstract][Full Text] [Related]
33. Avoid the trap: Targeting PARP1 beyond human malignancy.
Kim C; Chen C; Yu Y
Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
[TBL] [Abstract][Full Text] [Related]
34. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
35. The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis.
Liu L; Li J; Ke Y; Zeng X; Gao J; Ba X; Wang R
Cell Mol Life Sci; 2022 Jan; 79(1):60. PubMed ID: 35000037
[TBL] [Abstract][Full Text] [Related]
36. The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Lakatos P; Hegedűs C; Salazar Ayestarán N; Juarranz Á; Kövér KE; Szabó É; Virág L
Mutat Res; 2016 Aug; 790():31-40. PubMed ID: 27427773
[TBL] [Abstract][Full Text] [Related]
37. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Karpova Y; Wu C; Divan A; McDonnell ME; Hewlett E; Makhov P; Gordon J; Ye M; Reitz AB; Childers WE; Skorski T; Kolenko V; Tulin AV
Biochem Pharmacol; 2019 Sep; 167():149-162. PubMed ID: 30880062
[TBL] [Abstract][Full Text] [Related]
38. High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection.
Kotova E; Tulin AV
Methods Mol Biol; 2017; 1608():299-312. PubMed ID: 28695517
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
40. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
